×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
Back to Agenda
Real-World Response: Harnessing Electronic Health Records to Develop Robust Clinical Endpoints in Solid Tumors
Session Chair(s)
Michael W. Lu, PharmD
Platform Strategy Leader, RWD, Personalized Healthcare Oncology
Genentech, A Member of the Roche Group, United States
RECIST-based response is an established endpoint in clinical trials, but how do you assess response in routine patient care? This session presents efforts to develop a real-world response endpoint and its utility in clinical development.
Learning Objective : Describe the utility of measuring treatment response in clinical trials and challenges of accessing it in routine clinical care; Discuss methods, data elements, and rigor needed to evaluate this endpoint and future implications for clinical development.
Speaker(s)
Real-World Response: Harnessing Electronic Health Records to Develop Robust Clinical Endpoints in Solid Tumors
Ariel Bourla, MD, PhD
Flatiron Health, United States
Medical Director
Application of Real-World Response in Prospective Studies
Michael W. Lu, PharmD
Genentech, A Member of the Roche Group, United States
Platform Strategy Leader, RWD, Personalized Healthcare Oncology
Exploring Real-World Response and Progression Free Survival in the AACR GENIE Biopharma Collaborative
Gregory Riely, MD, PhD
Memorial Sloan Kettering Cancer Center, United States
Vice Chair, Clinical Research, Department of Medicine
Have an account?